Marra Paolo, Franchi-Abella Stephanie, Hernandez José A, Ronot Maxime, Muglia Riccardo, D'Antiga Lorenzo, Sironi Sandro
Department of Radiology, ASST Papa Giovanni XXIII Hospital, School of Medicine and Surgery, University of Milano Bicocca, Bergamo, Italy.
Department of Pediatric Radiology, DMU Smart Imaging, Bicêtre Hospital, AP-HP. Reference Centre for Vascular Diseases of the Liver, FSMR FILFOIE, ERN RARE LIVER, FHU Hépatinov, Le Kremlin-Bicêtre, France.
Eur Radiol. 2025 Jun;35(6):3262-3269. doi: 10.1007/s00330-024-11040-8. Epub 2024 Sep 6.
Portal hypertension resulting from non-cirrhotic extrahepatic portal vein obstruction (EHPVO) in children has been primarily managed with the Meso-Rex bypass, but only a few patients have a viable Rex recessus, required by surgery. This study reports a preliminary series of patients who underwent interventional radiology attempts at portal vein recanalization (PVR), with a focus on technical aspects and safety.
A retrospective review of consecutive patients with severe portal hypertension due to non-cirrhotic EHPVO at a single institution from 2022, who underwent percutaneous attempts at PVR, was performed. Technical and clinical data including fluoroscopy time, radiation exposure, technical and clinical success, complications and follow-up were recorded.
Eleven patients (6 males and 5 females; median age 7 years, range 1-14) underwent 15 percutaneous transhepatic (n = 1), transplenic (n = 11), or simultaneous transhepatic/transplenic (n = 3) procedures. Rex recessus was patent in 4/11 (36%). Fluoroscopy resulted in a high median total dose area product (DAP) of 123 Gycm (range 17-788 Gycm) per procedure. PVR was achieved in 5/11 patients (45%), 3/5 with obliterated Rex recessus. Two adverse events of grade 2 and grade 3 occurred without sequelae. After angioplasty, 4/5 patients required stenting to obtain sustained patency, as demonstrated by colour-Doppler ultrasound in all PVR after a median follow-up of 6 months (range 6-14).
Our preliminary experience suggests that 45% of children with non-cirrhotic EHPVO can restore portal flow even with obliterated Rex recessus. In non-cirrhotic EHPVO, PVR may be an option, if a Meso-Rex bypass is not feasible, although the radiation exposure deserves attention.
Innovative percutaneous procedures may have the potential to be an alternative option to the traditional surgical approach in the management of non-cirrhotic EHPVO and its complications in children not eligible for Meso-Rex bypass surgery.
Non-cirrhotic portal hypertension in children has been traditionally managed by surgery with Meso-Rex bypass creation. Percutaneous PVR may restore the patency of the native portal system even when the Rex recessus is obliterated and surgery has been excluded. Interventional radiological techniques may offer a minimally invasive solution in complex cases of EHPVO in children when Meso-Rex bypass is not feasible.
儿童非肝硬化性肝外门静脉阻塞(EHPVO)所致门静脉高压主要通过肠系膜上静脉-肝内门静脉左支分流术(Meso-Rex分流术)进行治疗,但只有少数患者具备手术所需的可行的雷克斯隐窝。本研究报告了一系列接受门静脉再通(PVR)介入放射学尝试的患者的初步情况,重点关注技术方面和安全性。
对2022年在单一机构接受经皮PVR尝试的因非肝硬化性EHPVO导致严重门静脉高压的连续患者进行回顾性研究。记录技术和临床数据,包括透视时间、辐射暴露、技术和临床成功率、并发症及随访情况。
11例患者(6例男性,5例女性;中位年龄7岁,范围1 - 14岁)接受了15次经皮经肝(n = 1)、经脾(n = 11)或同时经肝/经脾(n = 3)手术。11例中有4例(36%)雷克斯隐窝通畅。每次手术透视导致的中位总剂量面积乘积(DAP)较高,为1 Gycm(范围17 - 788 Gycm)。11例患者中有5例(45%)实现了PVR,其中3例雷克斯隐窝闭塞。发生了2例2级和3级不良事件,无后遗症。血管成形术后,5例患者中有4例需要置入支架以维持通畅,在中位随访6个月(范围6 - 14个月)后,所有PVR通过彩色多普勒超声证实。
我们的初步经验表明,45%的非肝硬化性EHPVO儿童即使雷克斯隐窝闭塞也能恢复门静脉血流。在非肝硬化性EHPVO中,如果Meso-Rex分流术不可行,PVR可能是一种选择,尽管辐射暴露值得关注。
在治疗不符合Meso-Rex分流手术条件的儿童非肝硬化性EHPVO及其并发症时,创新的经皮手术可能有潜力成为传统手术方法的替代选择。
儿童非肝硬化性门静脉高压传统上通过创建Meso-Rex分流术进行手术治疗。即使雷克斯隐窝闭塞且已排除手术,经皮PVR仍可恢复天然门静脉系统的通畅。当Meso-Rex分流术不可行时,介入放射学技术可为儿童复杂EHPVO病例提供微创解决方案。